— Why it moved
Why CRVO Stock Tripled Today — June 16, 2026
A $10.5M lifeline plus a $3M insider buy from Vertex's founder took this 6M-float biotech from $2.48 to $7.45 by lunch, before it gave back nearly 40%.
## What moved it Two filings stacked. A $10.5M private placement pushed CervoMed's cash runway into Q2 2027, and a Form 4 showed board member Joshua Boger, the founder of Vertex, buying 955,000 shares for about $3M. An insider buy that size in a $20M biotech gets noticed fast.
## The mechanics Roughly 6.3M shares in the float and 200M traded, so the float turned over about 30 times. CervoMed has an FDA-aligned Phase 3 path for neflamapimod in dementia with Lewy bodies but no partner, and until this filing, not much cash. A real filing plus a tiny float is how a stock triples in a session.
## Numbers - Cap: ~$23M / float: 6.3M - Day volume: 200.7M (~478x avg) - Prev close: $2.48 → day high $7.45 (+200%) - 52w range: $2.13–$13.13
## Where it ended up Stock Pulse flagged it at 11:05 AM, $4.71. It climbed for another 94 minutes and topped at $7.45 at 12:39 PM, +58% from the alert. That peak was genuinely catchable — 1.5M shares traded in that minute alone. Then the air came out. It closed at $4.52, just under the alert price.
## Reality check - +58% at the peak, -4% at the close. Timing decided everything. - The financing is dilution, even when the press release calls it runway. - Insider buying is a datapoint, not a Phase 3 result. The trial still needs a partner to fund it.